[ A20-74] Entrectinib (solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion) - Benefit assessment according to §35a Social Code Book V

Last updated 18.02.2021

Project no.:

Commission awarded on 28.08.2020 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:


Solid tumours expressing an NTRK gene fusion, disease locally advanced or metastatic or where surgical resection is likely to result in severe morbidity: patients 12 years of age and older who have not received a prior NTRK inhibitor and who have no satisfactory treatment options

Result of dossier assessment:

Added benefit not proven due to lack of suitable study data


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Federal Joint Committee (G-BA)

2021-02-18: A G-BA decision was published.

G-BA documents on this decision


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form